Precision Medicine Update: Important Progress on the Long Road from Discovery to Population Health Impact
Impressive Pace and Potential The All of Us Research Program is an ambitious United States initiative launched in 2015 to collect health-related information on one million or more volunteers from diverse communities. A recent paper in the New England Journal of Medicine described progress and lays out the vision for the initiative moving forward. As Read More >
Posted on by Muin J. Khoury, Office of Public Health Genomics, Centers for Disease Control and Prevention, Atlanta Georgia and George A. Mensah, Center for Translation Research and Implementation Science, National Heart, Lung, and Blood InstituteLeave a commentTags population healthWhy should early career public health researchers pay attention to precision medicine?
In a recent commentary published in the American Journal of Public Health, I had the privilege of working with a group of early career investigators to begin a conversation about the impact that the debate between the utility of precision medicine and public health approaches is having as we begin our research careers. To begin, let’s Read More >
Posted on by Caitlin G. Allen, MPH, Doctoral Student, Behavioral Sciences and Health Education Department, Emory University Rollins School of Public Health, Atlanta, GeorgiaLeave a commentTags public health researcherPreventive medicine can be more precise and precision medicine can be more preventive!
In a recent JAMA viewpoint, Psaty and coauthors compare precision medicine and preventive medicine as two distinct models in medicine and public health. They use the example of hemophilia B to illustrate how new gene therapy can successfully target treatment with high specific-activity factor IX variant. They contrast this model of precision medicine with the Read More >
Posted on by Muin J Khoury, Director, Office of Public Health Genomics, Centers for Disease Control and Prevention1 CommentCan Genetic Risk Scores Score a Win for Precision Prevention? Time and Rigorous Studies Will Tell
In May 2018, CDC’s Office of Public Health Genomics, the National Cancer Institute’s Division of Cancer Control and Population Sciences, and the National Heart, Lung, and Blood Institute’s Center for Translation Research and Implementation Science held a special webinar titled: “Using Genetic Risk Scores in the Prevention and Control of Common Diseases: Opportunities and Challenges.” Read More >
Posted on by Muin J. Khoury, Office of Public Health Genomics, Centers for Disease Control and Prevention, Atlanta, Georgia; Debbie Winn, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland; George A. Mensah, Center for Translation Research and Implementation Science, National Heart, Lung, and Blood Institute, Bethesda, MarylandLeave a commentCategories precision medicine
Evaluating the Impact of Precision Medicine: How Ivacaftor Reduces Hospitalizations of Patients with Cystic Fibrosis
Precision medicine takes into account individual factors in treating disease, targeting interventions to patients that can benefit the most. Population-based studies evaluating precision medicine approaches are important to determine whether the field can fulfill its promise for improved health outcomes. A prime example of precision medicine is ivacaftor, a small molecule drug originally developed to Read More >
Posted on by Ridgely Fisk Green, Office of Public Health Genomics and Scott Grosse, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and PreventionLeave a commentTags cystic fibrosis, ivacaftorPrecision Medicine in Action: How well does cascade screening for hereditary conditions work in the real world?
An important component of precision medicine is the identification, through genetic testing, of people who are at elevated risk of disease because of pathogenic germline mutations. Cascade screening involves contacting relatives of patients with certain hereditary conditions to help inform, manage, and identify those who may be at increased risk. A systematic scoping review on Read More >
Posted on by W. David Dotson, Office of Public Health Genomics, Centers for Disease Control and Prevention, Megan C. Roberts, Division of Cancer Control and Population Sciences, National Cancer Institute and Muin J. Khoury, Office of Public Health Genomics, Centers for Disease Control and PreventionLeave a commentCategories precision medicine
Tags cascade screening, precision medicineGenomics and Precision Medicine: How Can Emerging Technologies Address Population Health Disparities? Join the Conversation.
Advances in genome sequencing, other “omic” technologies, and big data promise a new era of personalized medicine. However, there is an ongoing discussion how these new technologies can be used to understand and address existing population health disparities. On October 11, 2017, the Precision Medicine and Population Health Interest Group in the Division of Cancer Read More >
Posted on by Wylie Burke, Professor Emeritus and former Chair, Department of Bioethics and Humanities, University of Washington, Charles Rotimi, Director, Center for Research on Genomics and Global Health, National Human Genome Research Institute, National Institutes for Health, Debbie Winn, Division of Cancer Control and Population Sciences, National Cancer Institute, Vence Bonham and Michael Hahn, National Human Genome Research Institute, National Institutes for Health, Muin J, Khoury, Office of Public Health Genomics, Centers for Disease Control and Prevention1 CommentTags health diparitiesIntegrating genomics into population-based cancer surveillance in the era of precision medicine
Population-based cancer surveillance provides a quantitative measurement of cancer occurrence in the United States and globally. Core activities of surveillance include measuring cancer incidence and characterizing each cancer with regard to histopathology, stage, and treatment in the context of survival. Cancer surveillance has been crucial in informing policy and practice, as well as clinical and Read More >
Posted on by Muin J. Khoury, Office of Public Health Genomics, Centers for Disease Control and Prevention, Atlanta, Georgia and Lynne Penberthy, Division of Cancer Control and Population Sciences, National Cancer InstituteLeave a commentTags precision medicine, surveillanceGenome Sequencing for Healthy Individuals? Think Big and Act Small!
In a 2013 blog post, we asked the question: “When should we all have our genomes sequenced?” At that time, we concluded that the time is not right and that “if we want to use whole genome sequencing in the course of regular preventive care and health promotion, research should be conducted to evaluate its Read More >
Posted on by Muin J. Khoury, Director, Office of Public Health Genomics, Centers for Disease Control and Prevention, and Greg Feero, guest blogger, Maine Dartmouth Family Medicine ResidencyLeave a commentTags genetic testing, population healthPrecision Public Health: More Precision Ahead for Individual and Population Interventions
In August 2016, we published a point-counterpoint viewpoint asking a crucial question that has been on the minds of researchers, health care providers and the public health community: “will precision medicine improve population health?” We understood that we were tackling “the elephant in the room” and hoped for reactions to this viewpoint. We were pleased Read More >
Posted on by Muin J. Khoury, Director, Office of Public Health Genomics, Centers for Disease Control and Prevention, Atlanta, Georgia, and Sandro Galea, Dean, School of Public Health, Boston University, Boston, Massachusetts2 CommentsTags precision public health, public health
.png)
No hay comentarios:
Publicar un comentario